Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
MGI sale comes less than two weeks after the biopharma said it was exploring "strategic alternatives."
You may also be interested in...
Epizyme Builds A Cancer Company At Mach Speed
Epizyme’s recent alliance with Celgene validates industry’s interest in histone methyltransferase inhibitors, a kinase-like class of epigenetic enzymes. Celgene’s willingness to cede US rights in return for access to preclinical assets belies HMTs’ novelty and helps to position Epizyme for potential success as a US-focused oncology company. Despite the strong start, it won’t be easy.
BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion
The new deal enables BMS to smooth out its earnings in the face of a looming patent cliff and gives Otsuka an entrée into oncology.
BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion
The new deal enables BMS to smooth out its earnings in the face of a looming patent cliff and gives Otsuka an entrée into oncology.